Inclisiran - Lipid modification
You are here : Home > Formulary Search > Inclisiran - Lipid modification
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
Green
Formulations :
- Subcutaneous injection (sc)
Formulary Status :
Associated Icons :
Restrictions / Comments :
Important
Prescribing in secondary care is commissioned by NHSE - Blueteq forms are required.
Documentation
NICE Technology Appraisal
PAD Profile
ChemicalSubstance :
Inclisiran
Indication :
Lipid modification
Group Name :
Keywords :
primary hypercholesterolaemia, mixed dyslipidaemia, lipid-lowering, lipid lowering
Brand Names Include :
Leqvio
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
5
Other Indications
Below are listed other indications that Inclisiran is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Lipid modification.
Committee Recommendations (1)
Decision reviewed March 2022
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia in line with NICE TA733
A GREEN traffic light status will be applied to inclisiran.
Key points:
- It should be a shared decision making process between the patient and the prescribing clinician in line with NICE.
- Patient should be on maximum tolerated lipid-lowering therapy prior to initiation with inclisiran.
- Can be used in combination with statins or other lipid lowering treatments OR
- As monotherapy only if a person was unable to take any other type of lipid-lowering therapy